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Progress in genomics and other high throughput “-omic” technologies is promising to 
revolutionize the practice of epidemiology by providing new tools to measure exposures, 
susceptibility, and disease outcomes. New platforms of bio-marker measurement are 
becoming increasingly available for epidemiologic studies. Examples include genomic, 
proteomic, metabolomic, noncoding RNA, epigenomic, mitochondrial DNA, telomerase, 
and microbiota studies. In addition, environmental measurements are becoming increasingly 
sophisticated, and the exposome holds promise with regard to measuring the impact of 
multiple exposures on health outcomes (1).
Omic technologies pose many challenges regarding the collection, analysis, validation, 
replication, and eventual utility of this information for medicine and public health (2). We 
should always be mindful of the potential pitfalls of adopting new technologies too soon. 
Because of this, the relationship between technologies and epidemiology is bidirectional. 
Although new omic technologies provide the tools to enhance epidemiologic research, 
epidemiology is needed to test and validate the application of these technologies for use in 
population settings (3).
Despite their tremendous appeal, it is premature to predict how new omic approaches will 
evolve over time. Likewise, we cannot anticipate what new platforms will be available and 
ready for research or clinical use, although our measurement capacity is likely to expand 
rapidly. What should be anticipated, however, is the need for an epidemiologic foundation 
for proper techniques for collection, sampling, processing, and storage of biologic 
specimens to be studied with these evolving technologies and development of principles for 
their optimal use, analysis, and validation in epidemiologic studies of all types. This need is 
particularly felt for cohort studies that collect biologic samples today but may assay those 
samples years if not decades into the future (1).
Analytic methods for omic technology platforms need to evolve and account for platform-
specific peculiarities as well as study design issues. A greater challenge is how to integrate 
multiple platforms within the same analysis. As the possibilities for false leads increase 
exponentially with each new omic technology, methodologic work is essential in evaluating 
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any technology's analytic performance, reproducibility, replication, disease associations, 
ethical and legal issues, and clinical use (2).
In order to inform our audience of the various omic fields, the Journal will publish a primer 
series for the epidemiologist interested in education about specific omic methods and 
technologies. Specifically, the series will inform epidemiologists how to read papers on the 
topics and what to do if they are interested in integrating emerging methods into their work.
In the present issue of the Journal, 2 articles represent the first installment of publications in 
this new series. Tzoulaki et al. (4) address the promise, design, and analysis of 
metabolomics studies in epidemiologic research. Nair et al. (5) review the study of 
microRNAs in human disease. What these articles have in common is that they address a 
series of questions and issues that are common to all of these technologies to educate the 
epidemiologist. What is the technology? What has been done in the field in the form of a 
synopsis of relevant original research publications, reviews, and meta-analyses? What are 
the main epidemiologic and statistical methods and software for design and analyses? What 
are the current methodological limitations of this technology in terms of measurement and 
statistical/analytical methods? What are the future prospects for this technology in the 
practice of epidemiology?
Proposed topics in this series will include, among others, epigenetics, the microbiome, 
proteomics, pathogen whole-genome sequencing, metagenomics, telomerases, and the 
exposome. We hope our readers will find these articles informative. We also invite 
prospective authors to submit articles to be considered for publication in the Journal's series 
on the Practice of Epidemiology.
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